Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
Gemogenovatucel-T is an autologous tumour cell vaccine manufactured from harvested tumour tissue. It reduces expression of furin and downstream TGF-β1...
Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial
Survival outcomes for patients with recurrent or advanced cervical cancer are poor. GX-188E vaccination has been shown to induce human papillomavirus...
Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial
Long-term follow-up results for the Costa Rica Vaccine Trial. Women aged 18–25 years were enrolled in the trial between June 28, 2004, and Dec 21, 200...
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Venetoclax is a highly selective, potent, oral BCL-2 inhibitor, which induces apoptosis in multiple myeloma cells. It has shown encouraging clinical e...
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials
Analysis of six randomized phases 3 trials were done to investigate non-inferiority of 3 months versus 6 months of adjuvant chemotherapy. For patients...
Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis
There is a scarcity of data exploring the benefits of adjuvant or neoadjuvant chemotherapy in the treatment of breast cancer in older women. We used d...
Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial
EORTC 22922/10925 was a randomized, phase 3 trial done across 46 radiation oncology departments from 13 countries. 15-year follow-up of 554 patients i...
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol
Lung-MAP (S1400) was created to establish an infrastructure for biomarker screening and rapid regulatory intent evaluation of targeted therapies. Elig...
Recent Posts
-
-
What Causes Sciatica | Dr. Kalyan Bommakanti
11 May 2022 -
